人白介素11在弥漫性大B细胞淋巴瘤中的表达及其与患者化疗后血小板减少的相关性

发布时间：2018-05-14 18:54

本文选题：弥漫性大B细胞淋巴瘤 + 白介素基因　；参考：《中国肿瘤生物治疗杂志》2017年11期

【摘要】：目的:检测人白介素11(interleukin-11,IL-11)基因在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)患者组织和血清标本中的表达,探讨IL-11表达与DLBCL患者预后的关系及其对化疗后患者血小板减少的影响。方法:收集2012年1月至2016年12月于河北省邯郸市第一医院血液科确诊的88例DLBCL患者和42例反应性淋巴增生(reactive lymphoid hyperplasia,RLH)患者组织和血液标本。用q PCR方法检测肿瘤组织和血液中IL-11的表达,应用单因素和多因素Cox回归分析IL-11表达与DLBCL患者临床病理特征和预后的关系以及影响患者预后的独立因素,相关性分析DLBCL患者IL-11表达和化疗后血小板减少的关系,Kaplan-Meier法分析IL-11表达与DLBCL患者总生存(OS)时间、无进展生存(PFS)时间的关系。结果:与对照组RLH患者比较,IL-11在DLBCL患者组织和血液中表达显著升高(组织:7.002±0.357 vs 1.507±0.139;血液:6.700±0.337 vs1.446±0.126,均P0.01)。IL-11表达与DLBCL患者的肿瘤大小、临床分期、B细胞症状、化疗敏感性及IPI指数相关(均P0.01),IL-11高表达患者OS和PFS较IL-11低表达患者明显缩短(均P0.01)。单因素及多因素Cox回归分析显示,IL-11表达、化疗敏感性和IPI指数是影响DLBCL患者预后的独立因素。化疗后血小板减少患者血清IL-11基因表达与血小板计数呈负相关(r=-0.732,P0.01)。结论:IL-11在DLBCL患者组织和血液中高表达,IL-11高表达DLBCL患者OS和PFS明显缩短,化疗后血小板减少严重。IL-11有望成为DLBCL患者独立的预后评判生物学标志物。
[Abstract]:Objective: to investigate the expression of interleukin-11 (IL-11) gene in tissue and serum of patients with diffuse large B-cell lymphoma (DLBCL), and to explore the relationship between the expression of IL-11 and prognosis of DLBCL patients and its effect on thrombocytopenia after chemotherapy. Methods: from January 2012 to December 2016, the tissues and blood samples of 88 patients with DLBCL and 42 patients with reactive lymphoproliferative lymphoid hyperplasias (RLHs) were collected from Hematology Department of the first Hospital of Handan City, Hebei Province. The expression of IL-11 in tumor tissue and blood was detected by Q PCR method. The relationship between IL-11 expression and clinicopathological characteristics and prognosis of DLBCL patients was analyzed by univariate and multivariate Cox regression analysis. The relationship between IL-11 expression and thrombocytopenia after chemotherapy in DLBCL patients was analyzed by Kaplan-Meier method. Results: compared with the control group, the expression of IL-11 in the tissue and blood of DLBCL patients was significantly higher than that in the control group (tissue: 7.002 卤0.357 vs 1.507 卤0.139; blood: 6.700 卤0.337 vs1.446 卤0.126). The expression of IL-11 was correlated with the tumor size, clinical stage and B cell symptoms of DLBCL patients. The chemosensitivity and IPI index were significantly shorter in patients with high expression of IL-11 than in patients with low expression of IL-11 (P 0.01). Univariate and multivariate Cox regression analysis showed that IL-11 expression, chemosensitivity and IPI index were independent factors influencing the prognosis of DLBCL patients. There was a negative correlation between the expression of serum IL-11 gene and platelet count in patients with thrombocytopenia after chemotherapy. Conclusion the high expression of IL-11 in the tissues and blood of DLBCL patients with high expression of IL-11 in DLBCL patients with significantly shortened OS and PFS, the severe thrombocytopenia after chemotherapy. IL-11 may be an independent prognostic biomarker for DLBCL patients.
【作者单位】：河北省邯郸市第一医院血液科;
【分类号】：R733

【相似文献】